Comment on

• Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.

  Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, Bovi JA, Robinson C, Konski A, Khuntia D, Grosshans D, Benzinger TLS, Bruner D, Gilbert MR, Roberge D, Kundapur V, Devisetty K, Shah S, Usuki K, Anderson BM, Stea B, Yoon H, Li J, Laack NN, Kruser TJ, Chmura SJ, Shi W, Deshmukh S, Mehta MP, Kachnic LA; for NRG Oncology. Brown PD, et al. J Clin Oncol. 2020 Apr 1;38(10):1019-1029. doi: 10.1200/JCO.19.02767. Epub 2020 Feb 14. J Clin Oncol. 2020. PMID: 32058845 Free PMC article. Clinical Trial.
• Hippocampal Avoidance Whole-Brain Radiotherapy (WBRT) Versus WBRT in Patients With Brain Metastases: Were Hippocampi the Only Difference?

  Levy A, Dhermain F, Botticella A, Rivera S, Le Péchoux C. Levy A, et al. J Clin Oncol. 2020 Oct 10;38(29):3453-3454. doi: 10.1200/JCO.20.00548. Epub 2020 Aug 12. J Clin Oncol. 2020. PMID: 32783669 No abstract available.
• Hippocampal Avoidance and Memantine for Whole-Brain Radiotherapy: Long-Term Follow-Up Warranted.

  Andratschke N, Belderbos J, Mayinger M, Schagen SB, De Ruysscher D. Andratschke N, et al. J Clin Oncol. 2020 Oct 10;38(29):3454-3455. doi: 10.1200/JCO.20.00747. Epub 2020 Aug 12. J Clin Oncol. 2020. PMID: 32783670 No abstract available.
• Meeting the Burden of Proof to Justify Intensity-Modulated Radiation for Brain Metastases.

  Chun SG, Klopp AH. Chun SG, et al. J Clin Oncol. 2020 Oct 10;38(29):3452. doi: 10.1200/JCO.20.00486. Epub 2020 Aug 12. J Clin Oncol. 2020. PMID: 32783671 No abstract available.